Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Zenas BioPharma, Inc. incurred convertible notes of $200,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 2.50% per year maturing April 1, 2032.
- Instrument
- convertible notes
- Principal
- $200,000,000 aggregate principal amount
- Counterparty
- U.S. Bank Trust Company, National Association
- Rate
- 2.50% per year
- Maturity
- April 1, 2032
- Event
- incurrence
Exact text from the filing
On March 31, 2026, Zenas BioPharma, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $200,000,000 aggregate principal amount of its 2.50% Convertible Senior Notes due 2032 (the “Notes”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Zenas BioPharma, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $200,000,000 aggregate principal amount (effective 2026-03-31).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- U.S. Bank Trust Company, National Association
- Value
- $200,000,000 aggregate principal amount
- Effective
- 2026-03-31
Exact text from the filing
Completed its public offering (the “Convertible Notes Offering”) of $200,000,000 aggregate principal amount of its 2.50% Convertible Senior Notes due 2032 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of March 31, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of March 31, 2026, between the Company and the Trustee.
View on SEC.gov